VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | BTK inhibitor-associated adverse events in patients with CLL

Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses BTK inhibitor-related adverse events in patients with chronic lymphocytic leukemia (CLL), comparing the toxicity profiles of non-specific BTK inhibitors and next-generation BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Dr Eichhorst receives honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter